rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

James E. Flynn

Director and 10% owner and Other role

Company insider

Files Form 4 as: Director and 10% owner and Other, Nuvalent; 10% owner and Other, Parabilis Medicines; Director and 10% owner and Other, Larimar Therapeutics; 10% owner, ARS Pharmaceuticals; Director and Other, Acutus Medical; Director and Other, BiomX; Director and 10% owner and Other, CareMax; Director and 10% owner and Other, DA32 Life Science Tech Acquisition.

Every Form 4 they filed

In numbers

Trades disclosed
439
Buys
43
Sells
59
Bought
$179.3M
Sold
$133.4M
Companies
46
Companies where not an officer
46
First trade
6 Feb 2006
Last trade
15 Jul 2026
Last filed
17 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
NuvalentDirector, 10% owner, Other · Biotechnology · last 15 Jul 20260 buys · 1 sell
PBLS Parabilis Medicines10% owner, Other · Biotechnology · last 11 Jun 20260 buys · 0 sells
LRMR Larimar TherapeuticsDirector, 10% owner, Other · Biotechnology · last 19 May 20261 buy · 0 sells
SPRY ARS Pharmaceuticals10% owner · Pharmaceuticals · last 27 Jun 20250 buys · 1 sell
Acutus MedicalDirector, Other · last 27 Jan 20251 buy · 0 sells
BiomXDirector, Other · Biotechnology · last 11 Jul 20240 buys · 0 sells
CareMaxDirector, 10% owner, Other · last 17 Nov 20230 buys · 0 sells
DA32 Life Science Tech AcquisitionDirector, 10% owner, Other · last 28 Jul 20230 buys · 0 sells
OncorusDirector · last 30 Dec 20221 buy · 6 sells
Singular Genomics Systemslast 1 Jun 20211 buy · 0 sells
HOWL Werewolf TherapeuticsBiotechnology · last 4 May 20211 buy · 0 sells
Terns Pharmaceuticalslast 9 Feb 20211 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jul 2026filed 17 Jul 2026NuvalentBiotechnologySEC FORM 4 Code D$1.0B8,299,225 at $124.00filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—43,000filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—20,000filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—20,000filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—15,000filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—15,000filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—3,789filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—3,789filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—4,147filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—4,147filing
15 Jul 2026filed 17 Jul 2026NuvalentBiotechnologySEC FORM 4 Code D$1.0B8,299,225 at $124.00filing
15 Jul 2026filed 17 Jul 2026NuvalentBiotechnologySEC FORM 4 Code D$80.6M650,000 at $124.00filing
15 Jul 2026filed 17 Jul 2026NuvalentBiotechnologySEC FORM 4 Code U$638K5,146 at $124.00filing
15 Jul 2026filed 17 Jul 2026NuvalentBiotechnologySEC FORM 4 Code U$638K5,146 at $124.00filing
15 Jul 2026filed 17 Jul 2026NuvalentBiotechnologySEC FORM 4 Code D$427K3,444 at $124.00filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D$337.0M2,717,627 at $124.00filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D$337.0M2,717,627 at $124.00filing
15 Jul 2026filed 17 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—43,000filing
16 Jun 2026filed 18 Jun 2026NuvalentBiotechnologySEC FORM 4 Code A—3,444 at $0.00filing
11 Jun 2026filed 11 Jun 2026PBLS Parabilis MedicinesBiotechnologySEC FORM 4 Code C—122,990filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care11
Financials7
Not placed84

Buys in green, sells in red, by the company’s sector.

Related people

John B. Harlow Jr.President and COO · President and COO at Larimar Therapeutics, filing Form 4 there in the last year
Craig TendlerDirector · Director at Parabilis Medicines, filing Form 4 there in the last year
RA CAPITAL MANAGEMENT, L.P.Director and 10% owner · Director and 10% owner at Parabilis Medicines, filing Form 4 there in the last year
James Richard PorterPresident and CEO · President and CEO at Nuvalent, filing Form 4 there in the last year
Benjamin LaneOfficer · Officer at Nuvalent, filing Form 4 there in the last year
Francis S. Soistman Jr.Director · Also traded EHTH in the last 90 days
Eric BjerkholtChief Financial Officer · Also traded MIRM in the last 90 days
Jolanda HoweSVP, Global Controller · Also traded MIRM in the last 90 days